Orris

Components of blood transfusion and there indications

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Searching Images

blood transfusion components packed red blood cells platelets plasma cryoprecipitate diagram

A clinical photograph depicting an apheresis procedure, specifically plateletapheresis, in a hospital or blood bank setting. A male donor is seated in a specialized blue reclining donor chair, connected to an automated blood cell separator (apheresis machine). The setup illustrates the extracorporeal circuit: blood is drawn through an intravenous line in the donor's arm, processed via a series of peristaltic pumps and a centrifugal separation chamber, and then returned. The machine features a monitoring screen and hangs several collection and infusion bags, containing red blood cells and amber-colored plasma or platelets, indicating the separation of blood components. A blood pressure cuff is visible on the donor's arm for monitoring hemodynamic stability during the procedure. This visual demonstrates the clinical application of medical technology in transfusion medicine for the collection of high-purity blood components like single-donor platelets.

A clinical photograph depicting an apheresis procedure, specifically plateletapheresis, in a hospital or blood bank setting. A male donor is seated in a specialized blue reclining donor chair, connected to an automated blood cell separator (apheresis machine). The setup illustrates the extracorporeal circuit: blood is drawn through an intravenous line in the donor's arm, processed via a series of peristaltic pumps and a centrifugal separation chamber, and then returned. The machine features a monitoring screen and hangs several collection and infusion bags, containing red blood cells and amber-colored plasma or platelets, indicating the separation of blood components. A blood pressure cuff is visible on the donor's arm for monitoring hemodynamic stability during the procedure. This visual demonstrates the clinical application of medical technology in transfusion medicine for the collection of high-purity blood components like single-donor platelets.

This medical illustration depicts a pathophysiology diagram of a therapeutic nanotechnology approach for treating atherosclerosis. The visual is divided into a longitudinal cross-section of a blood vessel and a detailed view of the microscopic components. The vessel shows a prominent atherosclerotic plaque characterized by a heterogeneous, lipid-rich core with internal cellular debris, causing significant luminal narrowing. Circulating within the vessel are red blood cells and various engineered nanoparticles. Key labeled components include mesoporous silica nanoparticles (MSN), shown as dark porous spheres; aCD47@MSN, representing MSN loaded with anti-CD47 antibody; and platelets/platelet vesicles. The primary therapeutic entity is the 'Anti-CD47 antibody@Platelet membrane coated MSN' (aCD47@PMSN), which consists of an antibody-loaded MSN core encapsulated in a semi-transparent red platelet membrane shell. Directional arrows illustrate the therapeutic mechanism: 'Targeting' of the plaque by aCD47@PMSN, 'Antibody release' into the lesion, and subsequent 'Efferocytosis' (clearance of necrotic cells). This diagram represents a biomimetic drug delivery system designed for cardiovascular intervention and immune-mediated plaque stabilization.

This medical illustration depicts a pathophysiology diagram of a therapeutic nanotechnology approach for treating atherosclerosis. The visual is divided into a longitudinal cross-section of a blood vessel and a detailed view of the microscopic components. The vessel shows a prominent atherosclerotic plaque characterized by a heterogeneous, lipid-rich core with internal cellular debris, causing significant luminal narrowing. Circulating within the vessel are red blood cells and various engineered nanoparticles. Key labeled components include mesoporous silica nanoparticles (MSN), shown as dark porous spheres; aCD47@MSN, representing MSN loaded with anti-CD47 antibody; and platelets/platelet vesicles. The primary therapeutic entity is the 'Anti-CD47 antibody@Platelet membrane coated MSN' (aCD47@PMSN), which consists of an antibody-loaded MSN core encapsulated in a semi-transparent red platelet membrane shell. Directional arrows illustrate the therapeutic mechanism: 'Targeting' of the plaque by aCD47@PMSN, 'Antibody release' into the lesion, and subsequent 'Efferocytosis' (clearance of necrotic cells). This diagram represents a biomimetic drug delivery system designed for cardiovascular intervention and immune-mediated plaque stabilization.

<table><tr><td>We recommend using cell salvage or an ultrafiltration device if large blood loss is anticipated.</td><td></td></tr><tr><td>Level of recommendation</td><td>1 (Strong)</td></tr><tr><td>Quality of evidence</td><td>B (Moderate)</td></tr><tr><td>If the intraoperative hemoglobin level is <10 g/dL and blood loss is ongoing, we recommend transfusion of packed blood cells along with fresh frozen plasma and platelets in a ratio of 1:1:1.</td><td></td></tr><tr><td>Level of recommendation</td><td>1 (Strong)</td></tr><tr><td>Quality of evidence</td><td>B (Moderate)</td></tr></table>

<table><tr><td>We recommend using cell salvage or an ultrafiltration device if large blood loss is anticipated.</td><td></td></tr><tr><td>Level of recommendation</td><td>1 (Strong)</td></tr><tr><td>Quality of evidence</td><td>B (Moderate)</td></tr><tr><td>If the intraoperative hemoglobin level is <10 g/dL and blood loss is ongoing, we recommend transfusion of packed blood cells along with fresh frozen plasma and platelets in a ratio of 1:1:1.</td><td></td></tr><tr><td>Level of recommendation</td><td>1 (Strong)</td></tr><tr><td>Quality of evidence</td><td>B (Moderate)</td></tr></table>

I now have all the information needed for a comprehensive, well-sourced answer. Let me compile it.

Components of Blood Transfusion and Their Indications

Blood component therapy replaced whole blood transfusion as the standard of care, allowing specific fractions to be administered according to each patient's deficit. The major components derived from whole blood are:

1. Packed Red Blood Cells (pRBCs)

What it is: Whole blood centrifuged to remove most plasma and platelets. Each unit (~200-350 mL) contains concentrated RBCs in an additive solution (e.g., SAGM). Can be stored up to 42-45 days at 1-6°C.
Effect: One unit raises adult hemoglobin (Hb) by approximately 1 g/dL and hematocrit by ~3%.
Indications:
  • Symptomatic anemia (fatigue, dyspnea, angina) regardless of Hb level
  • Restrictive threshold (general): Hb < 7 g/dL in most stable patients (supported by the landmark TRICC trial)
  • Hb < 8 g/dL for patients with cardiovascular disease, cardiac surgery, or orthopedic surgery
  • No transfusion benefit when Hb > 10 g/dL
  • Acute blood loss with hemodynamic compromise (trauma, GI bleed, surgical hemorrhage)
  • Hypoproliferative bone marrow disorders (aplastic anemia, myelodysplasia)
  • Chronic hemolysis - sickle cell disease, thalassemia
  • Preoperative optimization in symptomatic anemia
Note: In actively bleeding patients, Hb alone should not be the sole trigger - clinical status, hemodynamics, and rate of blood loss must be factored in.
  • Tietz Textbook of Laboratory Medicine, 7th ed., p. 3743; Tintinalli's Emergency Medicine, p. 107

2. Fresh Frozen Plasma (FFP)

What it is: Plasma separated from whole blood and frozen within 8 hours of collection. Each unit is 200-250 mL and contains 1 IU/mL of ALL coagulation factors, fibrinogen (~2-4 mg/mL), anticoagulant proteins (Protein C, Protein S, Antithrombin). Stored frozen up to 1 year. Requires 15-20 minutes to thaw. Universal donor = AB+.
Indications:
  • Active bleeding with multiple coagulation factor deficiencies (DIC, massive hemorrhage, liver failure)
  • Factor deficiency when specific factor concentrate is unavailable (e.g., Factor V or XI deficiency)
  • Warfarin reversal with active bleeding or emergency surgery (where PCC is unavailable)
  • Massive transfusion protocol - in a 1:1:1 ratio with pRBCs and platelets
  • Thrombotic thrombocytopenic purpura (TTP) - as plasma exchange fluid
  • Inherited or acquired coagulopathies
Dose: 10-20 mL/kg (raises coagulation factor levels by ~25-30%)
Important: Prophylactic FFP for mild coagulation abnormalities (INR < 1.5-2.0) in non-bleeding patients before procedures is not evidence-based and should be avoided.
  • Tietz Textbook of Laboratory Medicine, 7th ed., p. 3748; Tintinalli's Emergency Medicine, p. 107

3. Platelets

What it is: Collected either from pooled whole-blood donations (random donor concentrates) or via single-donor apheresis. Stored at 20-24°C with continuous agitation for up to 5 days (shortest shelf life of all blood products).
  • 1 apheresis unit (or 6 pooled random units) raises platelet count by ~50,000/mm³ in an adult
Indications:
SituationThreshold
Prophylaxis - stable patients< 10,000/mm³
Prophylaxis - fever/infection/procedure< 20,000/mm³
Minor invasive procedures (e.g., LP, bone marrow biopsy)< 50,000/mm³
Major surgery or active bleeding< 50,000-100,000/mm³
Neurosurgery or ocular surgery< 100,000/mm³
Massive transfusion protocolIn 1:1:1 ratio
  • Qualitative platelet dysfunction (uremia, antiplatelet drugs) with active bleeding, regardless of count
  • Dilutional thrombocytopenia during massive transfusion
Not indicated: In immune thrombocytopenic purpura (ITP) or TTP unless life-threatening bleeding, as transfused platelets are rapidly destroyed.
  • Tietz Textbook of Laboratory Medicine, 7th ed.; Tintinalli's Emergency Medicine, p. 108

4. Cryoprecipitate (Cryo)

What it is: The cold-insoluble precipitate formed when FFP is thawed at 1-6°C. Each unit (~15-20 mL) is rich in:
  • Fibrinogen (~150-300 mg/unit)
  • Factor VIII (~80-100 IU/unit)
  • von Willebrand factor (vWF)
  • Factor XIII
  • Fibronectin
Typically given as a pool of 5-10 units.
Indications:
  • Hypofibrinogenemia (fibrinogen < 100-150 mg/dL) with bleeding - DIC, massive transfusion, obstetric hemorrhage
  • Hemophilia A (Factor VIII deficiency) when Factor VIII concentrate is unavailable
  • von Willebrand disease (types 1 and 2) when desmopressin (DDAVP) fails and specific concentrates are unavailable
  • Factor XIII deficiency with bleeding
  • Uremic bleeding (adjunct)
  • Topical fibrin sealant preparation
  • Tietz Textbook of Laboratory Medicine, 7th ed.; Fischer's Mastery of Surgery, 8th ed., p. 250

5. Granulocytes (Granulocyte Concentrates)

What it is: Collected by apheresis from stimulated donors. Must be transfused within 24 hours of collection. Each unit contains >1 × 10¹⁰ granulocytes.
Indications (very limited, rarely used):
  • Severe, prolonged neutropenia (ANC < 500/mm³) with life-threatening bacterial or fungal infection unresponsive to antibiotics/antifungals
  • Neonatal sepsis with marrow failure
  • Inherited neutrophil dysfunction (e.g., chronic granulomatous disease) with severe infection

6. Albumin

What it is: Derived from fractionated pooled plasma. Available as 4-5% (iso-oncotic) or 20-25% (hyperoncotic) solutions. Pathogen-reduced.
Indications:
  • Large-volume paracentesis (> 5L) - to prevent post-paracentesis circulatory dysfunction (8 g albumin per liter removed)
  • Spontaneous bacterial peritonitis (SBP) - to reduce hepatorenal syndrome risk
  • Hypoalbuminemia with hemodynamic instability (fluid resuscitation, severe burns)
  • Hepatorenal syndrome as part of treatment protocols

7. Whole Blood

What it is: Unfractionated blood containing all components. Rarely stocked in civilian blood banks. Stored at 1-6°C for up to 35 days.
Indications:
  • Massive/combat trauma (military setting)
  • Exchange transfusion in neonates
  • Some massive transfusion protocols as an alternative to 1:1:1 component ratios

Massive Transfusion Protocol (MTP) Summary

Triggered when > 10 units pRBCs are anticipated within 24 hours:
  • Ratio: pRBC : FFP : Platelets = 1:1:1
  • Add cryoprecipitate when fibrinogen < 150 mg/dL
  • Consider tranexamic acid (TXA) within 3 hours of injury
  • Avoid crystalloid dilution
Apheresis platelet collection procedure

Key Points Summary

ComponentMain ContentsKey IndicationStorage
pRBCsRBCsAnemia, blood loss (Hb < 7-8 g/dL)42 days, 1-6°C
FFPAll clotting factorsCoagulopathy, DIC, massive transfusion1 year frozen
PlateletsPlateletsThrombocytopenia < 10,000-50,0005 days, 20-24°C
CryoprecipitateFibrinogen, Factor VIII, vWFHypofibrinogenemia, Hemophilia A, vWD1 year frozen
GranulocytesNeutrophilsRefractory severe infection with neutropenia24 hours
AlbuminAlbuminLarge-volume paracentesis, SBPRoom temp
Sources: Tietz Textbook of Laboratory Medicine 7th ed. | Tintinalli's Emergency Medicine | Fischer's Mastery of Surgery 8th ed. | Miller's Anesthesia 10th ed.
This is a shared conversation. Sign in to Orris to start your own chat.